Select company
- Ticker/CompanyMarket Cap.
No results found
Select metric
Pick a metric...
Ticker Information
Ticker
MREOCompany Name
MEREO BIOPHARMA GROUP PLCSector
HealthcareIndustry
BiotechnologyExchange
NASDAQMEREO BIOPHARMA GROUP PLC - Enterprise Value over EBITDA Chart Analysis (TTM)
From
Zoom
1Y
3Y
5Y
10Y
MREO - EV/EBITDA Historical data
| Date | Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | Enterprise Value | Enterprise Value over EBITDA |
|---|---|---|---|
| 6/30/2025 | $ -49.23M | $ 208.58M | 0 |
| 3/31/2025 | $ -46.22M | $ 307.14M | 0 |
| 12/31/2024 | $ -42.44M | $ 313.46M | 0 |
| 9/30/2024 | $ 0 | $ 562.26M | 0 |
| 6/30/2024 | $ -35.67M | $ 497.22M | 0 |
| 3/31/2024 | $ 0 | $ 402.02M | 0 |
| 12/31/2023 | $ -27.34M | $ 369.35M | 0 |
| 6/30/2023 | $ -30.55M | $ 142.96M | 0 |
| 12/31/2022 | $ -40.01M | $ 40.29M | 0 |
| 6/30/2022 | $ -14.8M | $ 31.43M | 0 |
Key Performance Insights, Last 5 Years
- MEREO BIOPHARMA GROUP PLC's latest trailing twelve months (TTM) EV/EBITDA stands at 0.
- Over the past 5 years, MEREO BIOPHARMA GROUP PLC's average EV/EBITDA has been 1.44.
- The median EV/EBITDA for MEREO BIOPHARMA GROUP PLC during this period was 1.44
- MEREO BIOPHARMA GROUP PLC reached its highest EV/EBITDA over the past 5 years at 1.44.
- The lowest EV/EBITDA recorded by MEREO BIOPHARMA GROUP PLC in the same timeframe 1.44
MEREO BIOPHARMA GROUP PLC's EV/EBITDA vs. competitors
We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue
EV/EBITDA Benchmarks
Similar metrics to EV/EBITDA:
- Enterprise Value over EBIT - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest and taxes [EBIT].
- Enterprise Value - [Calculation] Enterprise value (EV) refers to the total value of a business and is frequently used as a more elaborate substitute for market capitalization. EV is calculated as a company's [MarketCap] plus its [Debt] minus cash and cash equivalents [CashnEq].
- Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) - [Calculation] EBITDA is a non-GAAP accounting metric that lets investors asses profitability net of expenses dependent on financing decision, tax strategy and depreciation schedules. It is calculated by adding depreciation and amortisation expenses [DepAmor] back to [EBIT].
- EBITDA Margin - [Calculation] A company’s [EBITDA] as a percentage of [Revenue]. Measures how much earnings a company produces for each dollar of revenue generated before interest, taxes, depreciation and amortization.
- Enterprise Value over Free Cash Flow - [Calculation] Measures a company’s Enterprise Value [EV] in relation to its Free Cash Flow [FCF].
Definition of Enterprise Value over EBITDA
[Calculation] Measures a company’s Enterprise Value [EV] in relation to its earnings before interest, taxes, depreciation, and amortization [EBITDA].EV / EBITDA
(=) EV/EBITDA EV/EBITDA for MEREO BIOPHARMA GROUP PLC is calculated as follows: EV [ $ 221.54M ] / EBITDA [ $ -198.09M ]
(=) EV/EBITDA [ 0 ] MREO - Enterprise Value over EBITDA, Last 5 years
1.44
Minimum
Dec 31, 2021
1.44
Maximum
Dec 31, 2021
1.44
Average
1.44
Median
EV/EBITDA Benchmark AnalysisMarket
The chart above depicts the distribution of EV/EBITDA for companies in the Total Stock Market. The average EV/EBITDA of the companies is 13.49 with a standard deviation of 7.66.
The following table provides additional summary stats:
EV/EBITDA in the Market:
| filtered constituents | 2.44K |
|---|---|
| min | 0.01 |
| max | 40.82 |
| average | 13.49 |
| median | 11.75 |
| std | 7.66 |